Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Ifupinostat Hydrochloride

The hydrochloride salt form of ifupinostat,, an inhibitor of both phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon administration, ifupinostat binds to and inhibits the activity and mediated signaling of both PI3K and HDAC. In addition, ifupinostat may also inhibit other signaling pathways. This may prevent growth of PI3K and/or HDAC-expressing tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	BEBT-908 hydrochloride PI3K/HDAC inhibitor BEBT-908
Code name:	BEBT 908 BEBT-908 BEBT908 CUDC 908 CUDC-908 CUDC908

Ifupinostat Hydrochloride

Search NCI's Drug Dictionary